SBI Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

SBI Securities’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-480	Closed	-$15.1K	–	4150
2026 Q2	$15.1K	Sell	480 -276	-37%	-$8.15K	﹤0.01%	1650
2026 Q1	$18.7K	Buy	756 +27	+4%	+$643	﹤0.01%	1484
2025 Q4	$17K	Buy	729 +309	+74%	+$6.88K	﹤0.01%	1508
2025 Q3	$8.27K	Buy	420 +11	+3%	+$226	﹤0.01%	1852
2025 Q2	$8.88K	Sell	409 -124	-23%	-$2.93K	﹤0.01%	1753
2025 Q1	$12.9K	Buy	533 +155	+41%	+$3.49K	﹤0.01%	1497
2024 Q4	$7.89K	Buy	+378	New	+$8.12K	﹤0.01%	1744

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

SBI Securities's CPRX Position: Q3 2026 in Review

SBI Securities sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 480 shares — an estimated $15.1K sold.

SBI Securities first reported a position in CPRX in Q4 2024 and held it in 7 quarters. The position peaked at $18.7K in Q1 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

SBI Securities reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
SBI Securities sold 480 Catalyst Pharmaceutical shares in Q3 2026, an estimated $15.1K.
SBI Securities first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 7 quarters.
SBI Securities's Catalyst Pharmaceutical position peaked at $18.7K in Q1 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.